Medical Information

Bedaquiline is a key drug in combination therapy for multidrug-resistant tuberculosis, but not all patients are suitable for its use. Patients with severe arrhythmias and hepatic impairment are among those requiring careful evaluation or even avoidance, and the risks and benefits must be fully weighed before treatment.

I. Patients with Severe Arrhythmias

1. Risk mechanism

Bedaquiline can prolong the QT interval and increase the risk of serious arrhythmias such as torsades de pointes. In patients with pre-existing severe arrhythmias, the risk is further increased.

2. Contraindications and precautions

Bedaquiline should be avoided in patients with a definite history of QT interval prolongation, torsades de pointes, severe ventricular arrhythmia, or uncontrolled arrhythmia.

3. High-risk factors

Bradycardia, electrolyte disorders (hypokalemia, hypomagnesemia), thyroid dysfunction, structural heart disease, and concomitant use of other QT-prolonging drugs increase the risk, and extra caution is required.

4. Monitoring requirements

If use is truly necessary, electrocardiography should be performed regularly before and during treatment to monitor the QT interval, and serum potassium and magnesium should be maintained within normal ranges.

5. Management principles

If significant QT interval prolongation or arrhythmia occurs, discontinue the drug and consult a cardiologist, and adjust the combination regimen if necessary.

II. Patients with Hepatic Impairment

1. Risk mechanism

Bedaquiline is metabolized by the liver, and hepatic impairment can affect drug clearance, increasing the risk of hepatotoxicity and drug accumulation.

2. Contraindications and precautions

Bedaquiline should be avoided in patients with severe hepatic impairment. Use with caution in patients with mild to moderate hepatic impairment, and adjust the monitoring frequency under medical guidance.

3. Monitoring requirements

Transaminases, bilirubin, and alkaline phosphatase should be tested regularly before and during treatment. If abnormalities occur, close follow-up is required.

4. Clinical symptoms

Fatigue, loss of appetite, nausea, vomiting, abdominal pain, jaundice, or dark urine suggest possible liver injury, and medical attention should be sought immediately.

5. Management principles

If drug-induced liver injury is suspected, suspend the drug and evaluate. If it is confirmed to be related to bedaquiline and severe, permanently discontinue the drug.

III. General Principles

1. Pre-treatment evaluation

Ask in detail about the history of arrhythmia, heart disease, liver disease, and concomitant medications, and perform electrocardiography and liver function tests if necessary.

2. Individualized decision-making

In principle, avoid use in patients with severe arrhythmia or severe hepatic impairment; for other patients, decide after weighing the benefits and risks.

3. Close monitoring

During treatment, regularly monitor electrocardiography, electrolytes, and liver function to detect and manage abnormalities promptly.

4. Patient education

Inform patients of the relevant risks, and tell them to seek medical attention immediately if palpitations, dizziness, syncope, or symptoms of liver injury occur, and not to stop or add drugs on their own.